Advertisement

Die adjuvante Chemotherapie beim Mammakarzinom

  • K. W. Brunner
Conference paper

Zusammenfassung

Die ersten klinischen Versuche mit der adjuvanten Chemotherapie begannen vor mehr als 20 Jahren. Sie erfolgten aus der Erkenntnis, daß die Prognose und die Heilbarkeit des operablen Mammakarzinoms nur zu einem beschränkten Teil von der Radikalität der lokalen therapeutischen Maßnahmen, wie Art der Operation oder Strahlentherapie, abhängt. Es setzte sich die Erkenntnis aufgrund zahlreicher retrospektiver und prospektiver Untersuchungen durch, daß in erster Linie das Vorhandensein oder Fehlen von Mikrometastasen zum Zeitpunkt der Primärbehandlung, die mit den heutigen klinischen Methoden nicht nachgewiesen werden können, den weiteren Verlauf der Krankheit bestimmt. Die Art der Lokalbehandlung vermag lediglich die Häufigkeit des Lokalrezidivs, nicht aber die langfristige Prognose zu beeinflussen [6, 15].

Abkürzungen

NSABP

National Surgical Adjuvant Breast Project

SWOG

South West Oncology Group

CALGB

Cancer and Leukemia Group B

OSAKO

Ostschweizerische Arbeitsgruppe für Klinische Onkologie

L-PAM

L-Phenylalaninmustard (Alkeran)

CMF

Cyclophosphamid, Methotrexat, 5-Fluorouracil

CMFVP

wie CMF plus: Vincristin, Prednison

FAC

5-Fluorouracil, Adriamycin, Cyclophosphamid

PF

L-PAM (Alkeran), 5-Fluorouracil

PFT

L-PAM (Alkeran), 5-Fluorouracil, Tamoxifen

LMF

Leukeran (Chlorambucil), Methotrexat, 5-Fluorouracil

RFS

Rezidivfreie Überlebensrate

TS

Ges amtüberlebensrate (Total Survival)

N 1–3

1–3 befallene axilläre Lymphknoten

N 4+

4 und mehr befallene axilläre Lymphknoten

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abu-Zahra H, McDonald B, Maus J et al. (1982) Effect of adjuvant radiotherapy and chemotherapy in operable cancer of the breast. Proc Am Soc Clin Oncol (Abstr) 1: 74Google Scholar
  2. 2.
    Bonadonna G, Valagussa P, Rossi A et al. (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5: 450–464PubMedGoogle Scholar
  3. 3.
    Bonadonna G, Valagussa P, Rossi A et al. (1981) Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: The Milan institute experience. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune & Stratton, New York, p 435Google Scholar
  4. 4.
    Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15PubMedCrossRefGoogle Scholar
  5. 5.
    Buzdar A, Smith T, Blumenschein G et al. (1981) Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: five-year results. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune & Stratton, New York, p 419Google Scholar
  6. 6.
    Cancer Research Campaign Working Party (1980) Cancer research campaign trial for early breast cancer. Lancet 2: 55–60Google Scholar
  7. 7.
    Cole MP (1968) Suppression of ovarian function in primary breast cancer. In: Forrest APM, Kunkler PB (eds) Prognostic factors in breast cancer. Livingstone, Edinburgh, pp 146–156Google Scholar
  8. 8.
    Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy of breast cancer. Cancer 44: 793–798PubMedCrossRefGoogle Scholar
  9. 9.
    Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733PubMedGoogle Scholar
  10. 10.
    Henderson IC, Canellos GP (1980) Medical progress, cancer of the breast: The past decade. N Engl J Med 302:17–30, 78–90PubMedCrossRefGoogle Scholar
  11. 11.
    Henderson IC, Gelman R, Leroy M et al. (1982) 15 versus 30 weeks of adjuvant chemotherapy for breast cancer patients with a high risk of recurrence: a randomized trial. Proc Am Soc Clin Oncol 1: 75Google Scholar
  12. 12.
    Howat JMT, Hughes R, Durning P, Crowther D et al. (1981) A controlled clinical trial of adjuvant chemotherapy in operable cancer of the breast. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grr’?ne & Stratton, New York, p 371Google Scholar
  13. 13.
    Hubay CA, Pearson OH, Marshall JS et al. (1980) Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guérin vaccination in stage II breast cancer: a preliminary report. Surgery 87: 494–501PubMedGoogle Scholar
  14. 14.
    Fisher B, Slack N, Katrych DL et al. (1975) Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534PubMedGoogle Scholar
  15. 15.
    Fisher B, Redmond C, Fischer ER, participating NSABP Investigators (1980) The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology: an overview of findings. Cancer 46: 1009–1025PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher B, Redmond C, Wolmark N, Wieand HS (1981) Disease-free survival at intervals during and following completion of adjuvant chemotherapy. Cancer 48: 1273–1280PubMedCrossRefGoogle Scholar
  17. 17.
    Lichter AS, Lippman ME, Moss EV de et al. (1982) The influence of primary breast cancer treatment - mastectomy or excisional biopsy plus radiation - on the ability to deliver adjuvant chemotherapy. Proc Am Soc Clin Oncol (Abstr) 1: 81Google Scholar
  18. 18.
    Margolskee HR, Straus MJ, Ambinder JM et al. (1982) Adverse effect of radiotherapy on chemotherapy dosage in breast cancer adjuvant therapy. Proc Am Soc Clin Oncol (Abstr) 1: 84Google Scholar
  19. 19.
    Meakin JW, Allt WEC, Beale FA et al. (1977) Ovarian irradiation and prednisone following surgery for carcinoma of the breast. In: Salmon SE, Jones SE (eds): Adjuvant therapy of cancer. Amsterdam, North-Holland, pp 9–95Google Scholar
  20. 20.
    Meakin JW, Allt WEC, Beale FA et al. (1979) Ovarian irradiation and prednisolone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 120: 1221PubMedGoogle Scholar
  21. 21.
    Meyer RN, Kjellgren K, Malmio K et al. (1978) Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088–2098CrossRefGoogle Scholar
  22. 22.
    National Surgical Adjuvant Breast Project (NSABP) (1981a) Progress Report Protocol B-09:June 30, 1981Google Scholar
  23. 23.
    National Surgical Adjuvant Breast Project (NSABP) (1981b) Progress Report Protocol B-05:June 30, 1981Google Scholar
  24. 24.
    Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307–1317PubMedGoogle Scholar
  25. 25.
    Powles T (1981) Adjuvant endocrine therapy. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune & Stratton, New York, p 305Google Scholar
  26. 26.
    Ragaz J, Goidie JH, Coldman A et al. (1982) Preoperative adjuvant chemotherapy for carcinoma of the breast. Proc Am Soc Clin Oncol (Abstr) 1: 87Google Scholar
  27. 27.
    Ravdin RG, Lewison EF, Slack NH et al. (1970) Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast cancer. Surg Gynecol Obstet 131: 1055–1064PubMedGoogle Scholar
  28. 28.
    Rivkin S, Glucksberg H, Foulkes M (1982) Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. Proc Am Soc Clin Oncol (Abstr) 1: 74Google Scholar
  29. 29.
    Rossi A, Tancini G, Marchini S et al. (1980) Response to secondary treatment after surgical adjuvant CMF for breast cancer. Proc Am Soc Clin Oncol (Abstr) 21: 190Google Scholar
  30. 30.
    Senn HJ, Jungi WF, Angwerd R (1981) Chemo- (Immuno) therapy with LMF + BCG in node-negative and node-positive breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune & Stratton, New York, p 385Google Scholar
  31. 31.
    Skipper HE (1980) Breast cancer treated by means of mastectomy and mastectomy followed by 12 or 6 cycles of CMF. Southern Research Institute, Birmingham, Ala. (Booklet 4)Google Scholar
  32. 32.
    Tancini G, Bonadonna G, Marchini S et al. (1982) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. Proc Am Soc Clin Oncol 1: 86Google Scholar
  33. 33.
    Tormey DC, Holland FJ, Weinberg V et al. (1981) 5-Drug versus 3-drug ± MER postoperative chemotherapy for mammary carcinoma. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune & Stratton, New York, p 377Google Scholar
  34. 34.
    Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patiens. Cancer 41: 1170–1178PubMedCrossRefGoogle Scholar
  35. 35.
    Walgren A, Baral E, Glas U et al. (1981) Adjuvant breast cancer treatment with tamoxifen and combination chemotherapy in postmenopausal women. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer IIl. Grune & Stratton, New York, p 345Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • K. W. Brunner

There are no affiliations available

Personalised recommendations